ABBV vs JNJ
ABBV and JNJ side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABBVAbbVie Inc. | JNJJohnson & Johnson |
|---|---|---|
| Market cap | $434.64B | $624.78B |
| P/E (TTM) | 69.5 | 30.1 |
| P/B | — | 7.35 |
| P/S | 7.1x | 6.6x |
| Dividend yield | 2.68% | 1.98% |
| Revenue | $61.16B(TTM) | $97.93B(TTM) |
| Revenue growth (YoY) | 8.6% | 6.0% |
| Net income | $6.31B(TTM) | $21.04B(TTM) |
| Earnings growth (YoY) | -1.2% | 90.6% |
| EPS, diluted | $3.54(TTM) | $8.62(TTM) |
| EBIT margin | 24.6% | 22.9% |
| ROE | — | 31.5% |
| ROIC | 18.6% | 16.1% |
| Piotroski F | — | 6/9 |
| 1y total return | +27.0% | +54.2% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: ABBV frente a JNJ
| Métrica | ABBV | JNJ |
|---|---|---|
| Valor final | $63.1K | $31.4K |
| Retorno total | +530.7% | +213.7% |
| CAGR | +19.5% | +11.7% |
| Volatilidad | 25.8% | 18.5% |
| Sharpe | 0.67 | 0.48 |
| Sortino | 0.94 | 0.69 |
| Caída máxima | -45.1% | -27.4% |
Basado en 2600 días de negociación comunes, 2016-04-06 → 2026-08-07 · tasa libre de riesgo 3.87% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)